"Medical headliner" K medicine again "King fried" O drug hit the stomach cancer "mountain"

(2020/09/24) 751 varieties to be evaluated Why this year's health insurance is not so attractive; Novarda Zolgensma expansion hindered by the FDA Roche / Yan Jian may benefit; Howson Pharmaceuticals: 6 heavy-duty new products approved First rate of more than 80% 14 new drugs to be approved ... (Click on the title, available in the original article) Novartis Zolgensma expansion by the FDA blocked Roche / Yan Jian or can benefit from the latest animal safety data, Novartis had planned to complete in 2021 to the FDA to submit Zolgensma new dosage form of the market application, with a view to expanding its gene therapy to older patients with spinal myotrophy.
now, that hope has been dashed and animal testing is not enough.
: That's good news for rivals Yan Jian and Roche.
751 varieties to be evaluated Why this year's health insurance is not so attractive in countries around the world's health insurance catalog access, pharmaceutical companies are opportunities, in China is no exception.
varieties into health insurance, as if the yellow robe plus body, flying yellow Tengda finger to stay.
the varieties that linger outside the health-care catalogue, like breaking into a cold house, it's hard to turn around, it's a sight of the past.
, as health care reform deepens, the health-care catalog seems less enticing.
headlines: Why isn't health care so appealing to businesses? "Minenet" Howson Pharmaceuticals: 6 heavy-duty new products approved The first over-rated more than 80% of 14 new class 1 drugs were approved, Haussen Pharmaceuticals 1 new drug Amephenol amine nofowe tablets declared for listing and to be included in the priority review, is expected to become the company's 5th approved for the market of innovative drugs, this year Howson Pharmaceuticals has six new products approved (1 new class of drugs, 3 imitations).
meters of intranet data show that at present, Howson Pharmaceuticals has 16 varieties successfully evaluated (13 for the first), 5 varieties winning the bid for the third batch of national harvest; No first imitation has been approved, innovative drugs ushered in the outbreak period, 17 new drugs in the study of high-profile (14 for the first class of new drugs), of which 5 new drugs (including new adaptive disorders) have entered phase III clinical and later stages.
: 17 new drugs are in the spotlight.
66 exclusive imported drugs into the "quasi-medical insurance" five PD-1 unit price can reduce "geometry"? On September 18, the State Administration of Medical Security issued an announcement on the publication of the "Declaration List of Declared Drugs for Formal Review of the 2020 National Health Insurance Drug Catalog" (hereinafter referred to as the "Declaration List"), which showed that a total of 751 varieties had passed the formal examination.
: Is it feasible for PD-1 prices to be significantly reduced due to health care? Shell Society: K medicine again out of the "King fried" O drug on the stomach cancer "mountain" Hengxin Jun hundred and how? Recently, the 2020 European Esmo Esmo was successfully held online.
a top conference in the European oncology community, ESMO attracts a large number of oncologists to share the latest research and development developments and cutting-edge trends in the industry.
in the PD-1 segment, we found that the six PD-1 monoantigens currently listed in China all appeared at the ESMO Conference, and each announced its latest clinical research progress.
: Expect to see the efficacy of 1 plus 2.
.